Effect of Angiotensin Receptor Blocker and Angiotensin Converting Enzyme Inhibitor on Kidney Function and Blood Potassium Level in Indonesian Type 2 Diabetes Mellitus with Hypertension: A Three-Month Cohort Study.
UACR
angiotensin II receptor blockers
angiotensin-converting enzyme inhibitors
chronic kidney disease
eGFR
type 2 diabetes mellitus
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
03
2021
accepted:
10
06
2021
entrez:
15
9
2021
pubmed:
16
9
2021
medline:
16
9
2021
Statut:
epublish
Résumé
National formulary restrictions in Indonesia (2019) require estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m A prospective cohort study at RSUPN Dr. Cipto Mangunkusumo Hospital was conducted in 123 T2DM patients. We followed the study subjects prospectively for three months using a validated questionnaire, health record, and laboratory data. After 3 months of observation, there were no significant changes, except increased BMI values (p = 0.046) in the ACE-I group, and decreased LDL value (p = 0.016) and HDL value (p = 0.004) in the ARB group. Multivariate analysis showed that the consumption of ACE-I or ARB was not associated with a decrease/constant of UACR or increase potassium level, even after adjusting by confounding variables. Interestingly, we found ARB was more likely to increase eGFR, but the significance was lost once the duration of ACE-I/ARB use was entered into the model. In addition, BMI >25 kg/m ACE-I and ARB have a similar effect on UACR and blood potassium level, but ARB slightly increased eGFR compared to ACE-I within three months of consumption.
Identifiants
pubmed: 34522111
doi: 10.2147/DMSO.S310091
pii: 310091
pmc: PMC8434850
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3841-3849Informations de copyright
© 2021 Puspita et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
World J Diabetes. 2016 Mar 10;7(5):101-11
pubmed: 26981183
Diabetes Care. 2020 Aug;43(8):1977-1978
pubmed: 32503834
Metabolism. 2013 May;62(5):677-85
pubmed: 23260797
J Clin Endocrinol Metab. 2019 Apr 1;104(4):1171-1180
pubmed: 30398516
Am J Cardiovasc Drugs. 2014 Jun;14(3):167-73
pubmed: 24385234
Hypertension. 2003 Dec;42(6):1206-52
pubmed: 14656957
J Am Coll Cardiol. 2018 Apr 3;71(13):1474-1482
pubmed: 29598869
Hellenic J Cardiol. 2006 Jan-Feb;47(1):21-8
pubmed: 16532712
EClinicalMedicine. 2020 Dec 01;29-30:100662
pubmed: 33437955
J Res Pharm Pract. 2019 Oct 16;8(3):155-161
pubmed: 31728347
Am J Kidney Dis. 2016 May;67(5):728-41
pubmed: 26597926
Curr Pharm Des. 2013;19(17):3033-42
pubmed: 23176216
Cardiovasc Ther. 2012 Jun;30(3):e156-66
pubmed: 21883995
Age Ageing. 2018 Mar 01;47(2):269-274
pubmed: 29228124
J Obes. 2018 Oct 1;2018:4573258
pubmed: 30364090
J Am Heart Assoc. 2017 Jul 19;6(7):
pubmed: 28724651
BMJ. 2000 Dec 9;321(7274):1440-4
pubmed: 11110735
Int J Hypertens. 2020 Jul 29;2020:5342161
pubmed: 32802494
Med Care. 1986 Jan;24(1):67-74
pubmed: 3945130
Medicine (Baltimore). 2015 Sep;94(39):e1560
pubmed: 26426627
Trends Pharmacol Sci. 2011 Dec;32(12):734-9
pubmed: 21880378